Bioprocessing is undergoing a transformation, with products and processes that are more varied and challenging than ever before. Addressing this complexity requires a fundamental shift in the way that bioprocess development is undertaken, progressing
from a traditionally manual approach to one that embraces high-throughput technologies, advances in process measurement and control, and fully utilises the vast data generated.
- Explore best practices for generating structured data in an automated way
- Explore data requirements for some of the newer data science tools
- Explore the human and organisational challenges around adopting new technologies in bioprocessing
Data Scientists, Vice Presidents, Directors, Team Leads in Process Development and Biomanufacturing, Automation Engineers, Bioprocessing Scientists, High-Throughput Process Development Teams (HTPD), Upstream and Downstream Researchers, Cell Line Development
teams, IT teams wanting to learn more about development.
Moritz von Stosch, PhD
Chief Innovation Officer
Dr. Mortiz von Stosch is Chief Innovation Officer with DataHow AG. Prior to joining DataHow, he was Head of Process Systems Biology & Engineering Centre of Excellence at GSK Vaccines. Dr. von Stosch is an expert in hybrid modeling, multivariate data analysis, bioprocess development and optimization. He is the co-author of more than 30 publications including Hybrid Modelling Book in Process Industries. Dr. von Stosch received a Dipl.Ing. in Chemical Engineering (2006) from RWTH Aachen University.
John E. Harlan, PhD
Senior Principal Research Scientist, Global Protein Science
Dr. John E. Harlan is a Senior Principal Research Scientist in Pharmaceutical Discovery at AbbVie, Inc., located in North Chicago, Illinois. As part of Protein Sciences in Global Biologics Research, his work involves the production and characterization of protein therapeutic candidates across multiple therapeutic areas. In addition, his lab is actively exploring next-generation antibody-drug conjugation technologies. Prior to joining the Pharmaceutical Products Division of Abbott Laboratories as a staff scientist, Dr. Harlan did his post-doctoral training with Steve W. Fesik in the Structural NMR department at Abbott Laboratories. He received his PhD degree in Biochemistry from the Department of Biochemistry and Molecular Biology at the University of Chicago. For his doctoral work, he studied hydrodynamics and ligand interactions of prostaglandin H2 synthase 1 with Dr. R. Michael Garavito. Dr. Harlan received a BA in Biology and Chemistry from Alma College, Alma, Michigan.
Dr. Markus Gershater
Dr. Markus Gershater co-founded Synthace after working as a Research Associate in Synthetic Biology at University College London where he developed novel biosynthesis methods using pathway engineering. Prior to UCL, he was a Biotransformation Scientist at Novacta Biosystems working as part of the industrial biotechnology group that conducted more than 90 contract research projects for over 20 clients. Dr. Gershater has a PhD in Plant Biochemistry from Durham.
Synthace is the software company behind Antha, an integrated digital-to-physical: lab and data automation platform for biological experimentation. Our software enables users to dynamically design, execute, and replicate automated experiments, as well as collect and structure data from a variety of laboratory instruments reducing the time to biological insight. With an easy to use interface, it lowers barriers to multiple automation platforms, allowing non-specialists to easily generate analytics-ready structured datasets. We have partnered with Microsoft, Tecan, Merck, and Oxford Biomedica amongst others in areas such as high-throughput process development (HTPD) for downstream and upstream workflows. To read more about what our partners and clients have been able to achieve with the Antha platform, please visit this link: https://www.synthace.com/customers/case-studies/
Cost: No Cost!
Schedule conflict? Register and you'll receive a copy of the recording!